Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis

Jinhee Ahn, Hyun Jung Kim, Jong-Il Choi, Kwang No Lee, Jaemin Shim, Hyeong Sik Ahn and Young-Hoon Kim

PLOS ONE, 2017, vol. 12, issue 10, 1-13

Abstract: Background: Beta-blockers are first-line therapy in patients with congenital long-QT syndrome (LQTS). Objective: This study sought to determine the differences in effectiveness of beta-blockers on risk reduction according to LQTS genotype. Methods: We searched MEDLINE, EMBASE, and CENTRAL databases to investigate the use of beta-blockers (atenolol, nadolol, propranolol, and metoprolol) in patients with LQTS. Hazard ratio (HR) and relative risk (RR) were extracted or calculated from studies reporting cardiac events (syncope, aborted cardiac arrest (ACA), or sudden cardiac death (SCD)). Results: Among 2,113 articles searched, 10 studies (7 registry-based cohort studies (Cohort) and 3 interrupted time series studies (ITS)) involving 9,727 patients were included. In a meta-analysis using a random-effect model, the use of beta-blocker was associated with significant risk reduction of all cardiac events (HR 0.49, p

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0185680 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 85680&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0185680

DOI: 10.1371/journal.pone.0185680

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().